📊 ORGO Key Takeaways
Is Organogenesis Holdings Inc. (ORGO) a Good Investment?
Organogenesis is unprofitable with operating losses of $68.9M against $37.2M revenue, generating massive negative returns (ROE: -21.7%, ROA: -10.2%) despite moderate revenue growth of 17% YoY. While the company maintains adequate liquidity (3.53x current ratio) and generates positive free cash flow of $18.0M, the operational burn rate and inability to approach profitability at current scale present significant fundamental concerns without clear evidence of a path to sustainable operations.
Organogenesis delivers solid double-digit revenue growth and sharp YoY earnings improvement, supported by strong liquidity and low leverage. However, very thin gross margins and negative operating cash flow raise concerns about earnings quality and durability; sustained cash generation and margin stabilization are needed to merit a more positive stance.
Organogenesis Holdings Inc. Key Strengths (ORGO)
- Revenue growing at 17% year-over-year demonstrating market demand
- Positive free cash flow of $18.0M despite net losses, indicating strong working capital management
- Strong liquidity position with 3.53x current ratio and $91.4M cash reserve
- Double-digit revenue growth (+17% YoY) with improving operating and net margins
- Strong liquidity (3.3x quick), low leverage (0.21x D/E), and high interest coverage (39.4x)
- Healthy returns (ROE 12.3%, ROA 6.2%) indicating efficient capital use
ORGO Stock Risks: Organogenesis Holdings Inc. Investment Risks
- Deeply unprofitable with $53.2M net loss and $68.9M operating loss against only $37.2M revenue - unsustainable burn rate
- Negative returns on equity (-21.7%) and assets (-10.2%) indicate value destruction
- Anomalous gross margin of 169.1% (exceeding 100%) suggests unusual accounting adjustments or data quality issues requiring clarification
- Negative interest coverage ratio (-60.8x) indicates inability to service debt from operations
- No evident path to profitability or operating margin improvement at current operational scale
- Negative operating cash flow and FCF despite profitability, signaling weak cash conversion
- Thin gross margin (11.2%) heightens sensitivity to pricing/input costs and mix shifts
- Reimbursement/payer timing and collections risk that can extend cash cycles
Key Metrics to Watch
- Operating margin expansion and timeline to profitability
- Revenue growth acceleration needed to justify operating expense base
- Sustainability of positive operating cash flow as company scales
- Nature and magnitude of non-cash charges driving wedge between net income and cash flow
- Operating cash flow and FCF conversion vs. net income
- Gross margin trajectory and mix effects
Organogenesis Holdings Inc. (ORGO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 48.3% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 3.53x current ratio provides a solid financial cushion.
ORGO Profit Margin, ROE & Profitability Analysis
ORGO vs Healthcare Sector: How Organogenesis Holdings Inc. Compares
How Organogenesis Holdings Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Organogenesis Holdings Inc. Stock Overvalued? ORGO Valuation Analysis 2026
Based on fundamental analysis, Organogenesis Holdings Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Organogenesis Holdings Inc. Balance Sheet: ORGO Debt, Cash & Liquidity
ORGO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Organogenesis Holdings Inc.'s revenue has grown significantly by 21% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.04 reflects profitable operations.
ORGO Revenue Growth, EPS Growth & YoY Performance
ORGO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $37.2M | -$18.8M | $-0.17 |
| Q3 2025 | $115.2M | -$6.7M | $-0.05 |
| Q2 2025 | $101.0M | -$9.4M | $-0.10 |
| Q1 2025 | $86.7M | -$2.1M | $-0.02 |
| Q3 2024 | $108.5M | $3.2M | $0.02 |
| Q2 2024 | $117.3M | $2.3M | $0.02 |
| Q1 2024 | $107.6M | -$2.1M | $-0.02 |
| Q3 2023 | $108.5M | $215.0K | $0.00 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Organogenesis Holdings Inc. Dividends, Buybacks & Capital Allocation
ORGO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Organogenesis Holdings Inc. (CIK: 0001661181)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ORGO
What is the AI rating for ORGO?
Organogenesis Holdings Inc. (ORGO) has a Combined AI Grade of C from Claude (C) and ChatGPT (B) with 62% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ORGO's key strengths?
Claude: Revenue growing at 17% year-over-year demonstrating market demand. Positive free cash flow of $18.0M despite net losses, indicating strong working capital management. ChatGPT: Double-digit revenue growth (+17% YoY) with improving operating and net margins. Strong liquidity (3.3x quick), low leverage (0.21x D/E), and high interest coverage (39.4x).
What are the risks of investing in ORGO?
Claude: Deeply unprofitable with $53.2M net loss and $68.9M operating loss against only $37.2M revenue - unsustainable burn rate. Negative returns on equity (-21.7%) and assets (-10.2%) indicate value destruction. ChatGPT: Negative operating cash flow and FCF despite profitability, signaling weak cash conversion. Thin gross margin (11.2%) heightens sensitivity to pricing/input costs and mix shifts.
What is ORGO's revenue and growth?
Organogenesis Holdings Inc. reported revenue of $37.2M.
Does ORGO pay dividends?
Organogenesis Holdings Inc. does not currently pay dividends.
Where can I find ORGO SEC filings?
Official SEC filings for Organogenesis Holdings Inc. (CIK: 0001661181) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ORGO's EPS?
Organogenesis Holdings Inc. has a diluted EPS of $-0.44.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ORGO's fundamental grade?
Based on our AI fundamental analysis in May 2026, Organogenesis Holdings Inc. has a C grade with 62% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ORGO stock overvalued or undervalued?
Valuation metrics for ORGO: ROE of -21.7% (sector avg: 15%), net margin of -142.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ORGO's AI grade for 2026?
Our dual AI analysis gives Organogenesis Holdings Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ORGO's free cash flow?
Organogenesis Holdings Inc.'s operating cash flow is $21.1M, with capital expenditures of $3.1M. FCF margin is 48.3%.
How does ORGO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -142.8% (avg: 12%), ROE -21.7% (avg: 15%), current ratio 3.53 (avg: 2).